


ComAlign Handbook



ACURATE neo2™
Aortic Valve System


**Precision today,
access tomorrow.**



Today's TAVI population is increasingly lower-risk.¹

The number of lower-risk patients undergoing TAVI continues to grow.¹

In 2018, less than 2% of all TAVI patients were low-risk.
This population increased x14 in 2020, with 28% of reported TAVI procedures involving low-risk patients.¹




Lower-risk TAVI requires preserved future access.

A multi-center study (N = 118 patients presenting post-TAVI STEMI) observed higher PCI failure rates in TAVI patients with coronary access issues, highlighting the need of the techniques enhancing coronary access.²

STEMI following TAVI resulted in a **4x higher PCI failure rate and 33% increased mortality rate.**²


You require easy commissural alignment.

Optimizing commissural alignment in your practice may:



1

secure future coronary access³




2

allow for future intervention options³

Design that delivers best-in-class commissural alignment.

Three radiopaque commissural posts enable 3D verification of valve orientation in anatomy.



For best-in-class results: commissural alignment with self-expanding TAVI valves.


In the COMALIGN Study, ACURATE *neo2* was the only **self-expanding valve to 100% avoid moderate or severe commissural misalignment.**³



0% moderate or severe commissural misalignment

ACURATE *neo2* Valve


20/20 successful consecutive cases



10% moderate or severe commissural misalignment

Evolut R/PRO™ Valve

17/20 successful consecutive cases
3 cases with non-optimal rotations



25% moderate or severe commissural misalignment



Portico™ Valve

15/20 successful consecutive cases
5 cases difficult to assess

The COMALIGN *neo2* Study



The COMALIGN *neo2* Study demonstrated a correlation between commissural alignment and valve performance on ACURATE *neo2*. Severe misalignment (CMA) was associated with increased risk of severe patient-prosthesis-mismatch (PPM).

Severe Patient-Prosthesis Mismatch



Total Aortic Regurgitation was significantly higher in patients with severe commissurally misaligned valves.


Total Aortic Regurgitation*



The COMALIGN *neo2* study found that obtaining commissural alignment is easy when using the ACURATE *neo2* platform.

Immerse into a 3D commissural alignment experience

An advanced & realistic tool enabling you to experience & practice the commissural alignment technique with ACURATE *neo2*.



Try it now

Continue your learning journey on commissural alignment

Discover these useful courses from experts focusing on Commissural alignment and Coronary access.

Commissural Alignment & Coronary Access Series

[Learn now](#)

Expert	Affiliation
Dr. Henrik Bjursten	Skåne University Hospital Lund, Sweden
Dr. Matthias Gotberg	Skåne University Hospital Lund, Sweden
Prof. Ole de Backer	Rigshospitalet Copenhagen, Denmark
Dr. Darren Mylotte	University Hospital Galway, Ireland
Mohamed Abdel-Wahab	Leipzig Heart Center Leipzig, Germany

Get Full Acces now



Visit and Learn More:

www.bostonscientific.com/en-EU/products/transcatheter-heart-valve/acurateneo2-tavi-valve-system

* De Backer O. Commissural alignment & TAV performance: Results from the COMALIGN-neo 2 study. TCT 2023

1. TVT Registry.
2. Faroux L, et al. ST-Segment Elevation Myocardial Infarction Following Transcatheter Aortic Valve Replacement. "https://www.jacc.org/journal/jacc" J Am Coll Cardiol. 2021 May, 77 (17) 2187 -2199.
3. Bieliauskas, G, De Backer, O, Søndergaard, L, et al. Patient-Specific Implantation Technique to Obtain Neo-Commissural Alignment with Self-Expanding Transcatheter Aortic Valves. J Am Coll Cardiol 2021.

Illustrations for educational purposes only, not indicative of actual size or performance.
All photographs taken by Boston Scientific.

All trademarks are property of their respective owner. CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.

Boston Scientific
Advancing science for life™

www.bostonscientific.eu

© 2024 Boston Scientific Corporation or its affiliates. All rights reserved.

SH-1862003-AA